Clomiphene Citrate Capsules

Overview of Clomiphene Citrate Capsules

Dosage Strength

Compounded: 6.25, 12.5 mg, 25 mg Capsule
Commercial: 50 mg Tablet

General Information

A non-steroidal fertility drug called clomiphene is used to trigger ovulation in women who ovulate infrequently or don’t ovulate at all, including those with polycystic ovary syndrome (PCOS). Patients with an intact hypothalamic-pituitary-ovarian axis and ovaries capable of normal function can use the medication to induce ovulation. Due to its ease of use and inexpensive cost, clomiphene is frequently the first-line treatment for these patients. 80 percent of individuals who are properly selected will experience ovulation induction with clomiphene; around 40 percent of these patients will become pregnant within 6 cycles of treatment. Women who naturally ovulate on a regular cycle and take clomiphene do not experience an increase in pregnancy rates. Compared to the general population, clomiphene treatment is associated with only marginally higher rates of multiple births (3–5%). (1 percent ). If multiple gestation happens, it frequently results in twins. Less than 1% of women give birth to triplets or more. When used as a single agent, clomiphene has a substantially lower rate of multiparity than other fertility drugs (e.g., menotropins or FSH). Ovarian reserve can occasionally be determined using clomiphene as a diagnostic technique. In patients undergoing donor insemination, it is also used to control the timing of ovulation. It’s interesting to note that clomiphene has been applied to male patients with idiopathic oligospermia to improve sperm counts. Clomiphene was initially given FDA approval in 1967.

References

1.Potashnik G, Lerner-Gava L, Genkin L, et al. Fertility drugs and the risk of breast and ovarian cancers: results of a long-term follow-up study. Fertil Steril 1999;71:853-859.
2.Serophene (clomiphene citrate) package insert. Rockland, MA: EMD Serono; 2010 June.
3.Zuckerman H, Carmel S. The inhibition of lactation by clomiphene. J Obstet Gynaecol Br Commonw 1973;80:822-3.
4.Kroboth PD, Slalek FS, Pittenger AL et al. DHEA and DHEA-S: a review. J Clin Pharmacol 1999;39:327—48.
5.Cahill DJ, Fox R, Wardle PG, et al. Multiple follicular development associated with herbal medicine. Hum Reprod 1994;9:1469—70.
6.Duker EM, Kopanski L, Jarry H, et al. Effects of extracts from Cimicifuga racemosa on gonadotropin release in menopausal women and ovariectomized rats. Planta Med 1991;57:420—4.
7.Eagon PK, Tress NB, Ayer HA, et al. Medicinal botanicals with hormonal activity (abstract 1073). Proc Amer Assoc Cancer Res 1999:40.
8.Lieberman S. A review of Cimicifuga racemosa (black cohosh) for the symptoms of menopause. Journal of Women’s Health 1998;7:525—9.
9.Duffy C, Cyr M. Phytoestrogens: potential benefits and implications for breast cancer survivors. J Womens Health (Larchmt). 2003 Sep;12(7):617—31.
10.Clomid (clomiphene citrate) package insert. Bridgewater, NJ: Sanofi-Aventis US, LLC; 2012 Oct.

Legal Disclaimer: All information presented in this website is intended for informational purposes only and not for the purpose of rendering medical advice.

Get Started For $99 Initial Provider Consult